GLP-1 Medications: What the Weight Loss Drug Conversation Is Missing
Half of users stop within a year and most regain much of the weight, while muscle loss, shifting coverage, and real long-term costs decide who benefits.
GLP-1 medications for weight loss work well while they are taken, but the conversation misses what follows: roughly half of users stop within a year, most regain a large share of the lost weight, and part of the loss comes from muscle. The decisive questions concern cost, coverage, body composition, and an exit plan, not just pounds lost.
The public debate has settled on two numbers. The first is efficacy. The Wegovy pill produced a mean loss of 16.6 percent in its pivotal trial, and Eli Lilly’s Foundayo (orforglipron) averaged 12.4 percent at its highest dose.
Trending Now!!:
The SURMOUNT-5 head-to-head trial found 20.2 percent with tirzepatide (Zepbound) against 13.7 percent with semaglutide (Wegovy) over 72 weeks. Outside that direct comparison, the figures come from separate trials with different designs and cannot be ranked against each other.
The second number is the monthly price. Both matter. Neither describes what a patient lives with, because these drugs behave less like a course of treatment and more like a blood pressure medication: the benefit lasts about as long as the treatment does. In a KFF survey, about one in eight adults reported currently taking a GLP-1, so the distance between trial results and ordinary life now covers a very large population.
Most Patients Do Not Stay on Treatment
Real-world persistence is the least discussed number in obesity medicine. Prime Therapeutics followed commercially insured adults with obesity and without diabetes and found 31.5 percent still on therapy at one year, 15.1 percent at two years, and 8.1 percent at three.
Those cohorts began during the supply shortages, and newer data look better. One-year persistence among new Wegovy and Zepbound users rose from 33.2 percent for those who started in 2021 to 62.7 percent for those who started in 2024.
A pooled analysis of twelve real-world studies covering 445,897 people still put one-year discontinuation at 48.7 percent, with higher rates in people without diabetes. Type 2 diabetes offers little shelter.
Researchers at the American Diabetes Association’s annual sessions reported that nearly half of more than 18,000 patients stopped within a year, and stopping was linked to lower odds of reaching weight and HbA1c goals.
Cost, side effects, and a sense that the goal has been met are the usual reasons. The last of these is the costly misconception.
Reaching a target weight is not graduation; it is the point at which the drug is doing its job. Vivian Fonseca, who discussed the diabetes data, has stressed that setting expectations at the start is one of the most practical ways to reduce early dropout.
What Happens After the Last Dose
The strongest evidence on stopping comes from a BMJ analysis by Oxford researchers. People who stopped weight loss drugs regained weight about 0.3 kg a month faster than people who ended behavioral programs, regardless of how much they had lost.
Improvements in blood pressure, glucose, and cholesterol were projected to fade back to baseline in roughly 1.4 years. One author of the study described stopping as “taking their foot off the brake”. Lead author Sam West has been careful to note that regain follows weight loss of every kind; the difference with medication is speed.
A Cambridge meta-regression of six randomized trials covering more than 3,200 people gave a more granular picture. Participants regained about 60 percent of their lost weight by 52 weeks, and the model projects a plateau near 75 percent regained, which leaves roughly a quarter of the loss as a lasting benefit. The authors flagged what remains unknown: whether the regained tissue is fat, muscle, or both.
Not every study points the same way. An observational analysis of 7,938 patients in Diabetes, Obesity and Metabolism found that 35.2 percent received another obesity treatment within a year of stopping semaglutide or tirzepatide, and the analysis did not separate patients who regained from those who did not. Figures that look reassuring often include people who never fully left treatment.
Withdrawal trials also generally stop the drug outright, so how well a planned taper or lower maintenance dose could blunt regain remains an open question.
Weight Is the Wrong Scoreboard
Scale weight cannot distinguish fat from muscle, and that distinction decides what a patient is left with. Estimates of the lean share of GLP-1 weight loss vary widely, from roughly a quarter to as much as 40 percent, and a few early studies suggest more. The arithmetic matters: a patient who weighs 110 kg and loses 20 percent drops 22 kg, of which anywhere from 5.5 kg to nearly 9 kg could be lean tissue.
Some researchers argue the picture is less alarming than it sounds, pointing to trial data in which lean mass as a share of total body mass actually rose. Both statements can be true. Proportion improves while absolute muscle falls, and absolute muscle is what governs strength and mobility in later life.
Regain complicates things further. Rozalina McCoy, an endocrinologist at the University of Maryland School of Medicine, notes that people on these drugs lose fat, muscle, and bone mass but tend to regain mostly fat without regular exercise. Someone can return to the starting weight while being metabolically worse off. Chika Anekwe of the Massachusetts General Hospital Weight Center says the pattern matches what is seen in clinical practice.
Resistance training combined with adequate protein is the best-established countermeasure. Published targets run from about 1.2 to 1.6 grams of protein per kilogram of body weight daily, with some clinicians going higher, and two to three strength sessions a week is the common baseline.
The caveat is that this advice is extrapolated from general weight loss research, because randomized trials aimed specifically at GLP-1 users are scarce. Older adults, postmenopausal women, and people who start with low muscle mass face the greatest risk and have the most to gain from a plan on day one.
Structured nutrition guidance matters too, since eating much less can produce nutrient gaps alongside the weight loss.
The Price Is a Moving Target, and the Channel Matters
Price is the number everyone quotes and the one most often misread. List prices once exceeded $1,000 a month, with Wegovy at $1,349 and Zepbound at $1,086. Manufacturer agreements brought cash prices down sharply: the Wegovy injection at about $349 a month, Zepbound averaging about $346 through TrumpRx and as low as $299, and starter doses of the oral drugs at roughly $149.
Foundayo’s highest dose is $349 monthly, falling to $299 for patients who refill within 45 days. Annualized, a $299 to $349 monthly price comes to $3,588 to $4,188 a year, or roughly $10,800 to $12,600 over three years of continuous use. Starter prices apply to starting doses, so patients should price the maintenance dose, not the introductory one.
Choosing between Wegovy and Zepbound involves more than the efficacy gap. SURMOUNT-5 enrolled 751 adults without diabetes in an open-label design sponsored by Lilly.
Tirzepatide patients lost 20.2 percent against 13.7 percent, and 31.6 percent reached at least 25 percent loss versus 16.1 percent. The difference is large. Formulary placement, tolerability, and what a payer will cover often decide the prescription in practice.
The pill-versus-injection choice follows similar logic. The Wegovy pill must be taken on an empty stomach with a 30-minute wait before eating or drinking, while Foundayo has no timing restrictions. Its pivotal result came from a different trial than the Wegovy pill’s, so the two cannot be ranked directly.
Oral options are widening the front door: the Wegovy pill reached roughly 50,000 weekly prescriptions within weeks of launch, about 45,000 of them self-pay, a sign that cash channels are becoming a main route rather than a fallback.
Coverage Is Expanding in One Place and Shrinking in Another
The same drug carries different prices depending on the doorway. The Medicare GLP-1 Bridge, running from July 1 through the end of 2027, lets eligible Part D enrollees obtain the Wegovy pill and injection, Zepbound KwikPens, and Foundayo for a $50 monthly copay.
Prescribers must submit prior authorization showing the patient met clinical criteria tied to BMI and health conditions when therapy began.
The copay does not count toward the Part D out-of-pocket cap, and the Extra Help subsidy cannot be applied. According to KFF’s Juliette Cubanski, people already covered through Part D for conditions such as type 2 diabetes and sleep apnea are not eligible. What happens after the program ends remains unclear.
Employer coverage is moving the other way. A Business Group on Health survey found that the share of large employers covering GLP-1s for obesity fell from 72 percent to 60 percent in a single year, and roughly one in ten covering employers expect to drop the benefit for the coming plan year.
Per-unit prices have fallen, but total spending keeps climbing as more members use the drugs. Starbucks and Cigna have both ended coverage for their own employees. The implication for patients is blunt: coverage that exists at the start of treatment may not exist at month eighteen.
Compounded Semaglutide Is Not a Generic
Compounded semaglutide and tirzepatide filled the gap while branded supplies were short, and the legal basis for that has narrowed considerably. The FDA declared the tirzepatide shortage over in late 2024 and the semaglutide shortage over in early 2025.
Enforcement since then has come in waves: more than 40 warning letters to telehealth-linked compounders in late 2025, 30 more on March 3, and 25 on June 16, mostly over claims implying compounded products match approved drugs.
In May the agency proposed leaving semaglutide, tirzepatide, and liraglutide off the 503B bulks list. It has also flagged salt forms such as semaglutide sodium and semaglutide acetate as different active ingredients with no lawful basis for compounding. Adverse event reports tied to compounded versions reportedly exceeded 1,700 by May.
Hims & Hers, an early target, agreed with Novo Nordisk in March to offer branded semaglutide and stop advertising compounded versions except where medically necessary.
One misconception persists: compounded drugs are not generics. A generic must demonstrate equivalence to an approved product, while a compounded preparation demonstrates nothing of the kind. Patients weighing a cheaper route should ask which form of the molecule is used, which pharmacy fills it, and whether a clinician is monitoring dose and side effects.
Heart Protection Is Real but Narrower Than the Headlines
The SELECT trial enrolled 17,604 adults aged 45 and older with established cardiovascular disease and a BMI of at least 27, none with diabetes. Major cardiovascular events occurred in 6.5 percent of the semaglutide group and 8.0 percent of the placebo group, a 20 percent relative reduction and an absolute difference of 1.5 percentage points.
Primary prevention in people without existing heart disease was not studied. Treatment was also stopped because of adverse events by 16.6 percent of semaglutide patients versus 8.2 percent on placebo, about one extra discontinuation for every twelve treated. Those numbers show where the evidence is strongest, which is in patients with obesity and existing cardiovascular disease.
Stronger Drugs Raise the Same Questions
Retatrutide, Lilly’s triple agonist targeting GIP, GLP-1, and glucagon receptors, is the clearest sign of where the field is heading. In the TRIUMPH-1 trial, the 12 mg dose averaged 28.3 percent weight loss at 80 weeks, and an extension in patients with a BMI of 35 or higher reached 30.3 percent at 104 weeks.
Gastrointestinal effects were common, and urinary tract infections emerged as a new safety signal. The drug remains investigational.
A drug that removes 28 percent of body weight raises the stakes on every issue above: lean mass at risk, regain on withdrawal, and a bill that recurs for as long as the benefit is wanted.
A Continuity Test Before Starting
Four questions, asked before the first prescription, capture most of what the current conversation omits.
Coverage
The first question is whether the payer will cover the maintenance dose for the full planned duration, and what happens if employment, plan rules, or a program such as the Medicare Bridge changes.
Cost
The second is the monthly cost at the dose that will be taken long term, including the clinical visits that come with it, rather than the introductory price.
Composition
The third is body composition. A baseline measure of muscle, a strength training routine, and a daily protein target belong in the first weeks of treatment, not after the weight has already dropped.
Contingency
The fourth is the exit. Patients and clinicians should agree in advance on what happens if the drug is stopped, switched, or interrupted: how often weight is checked in the first year, what level of regain triggers a conversation, and whether restarting or moving to another treatment is the plan. Stopping without a plan is the pattern that produces the regain data.
GLP-1 medications for weight loss are among the most effective tools medicine has produced for obesity, and nothing in the evidence above argues otherwise.
The evidence argues for a different frame: a long-term therapy whose results depend on continuity, whose costs depend on the channel, and whose effects on the body, muscle in particular, depend on what accompanies the prescription.
Patients, employers, and public programs that plan only for the first twelve weeks will keep rediscovering the same outcome in months twelve through thirty-six.
What People Ask
